

NCT ID	NCT03940820
Title	Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors
Phase	Phase 1/Phase 2
Date Added	2019-05-07
Location	China
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	ROBO1 CAR-NK cells
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03874897
Title	Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Phase	Phase 1
Date Added	2019-03-14
Location	China
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	CAR-CLDN18.2 T-Cells, Chemotherapy, PD-1 Monoclonal Antibody
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06415851
Title	Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
Phase	Phase 2
Date Added	2024-05-15
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT04262687
Title	Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
Phase	Phase 2
Date Added	2020-02-10
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT04595266
Title	Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
Phase	Phase 2
Date Added	2020-10-20
Location	Spain
Prior IO Allowed	No

CRC-directed	Yes
Status	Active, not recruiting
Drugs	Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT02675946
Title	CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Phase	Phase 1
Date Added	2016-02-05
Location	California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maryland, United States Massachusetts, United States Nebraska, United States New Jersey, United States North Carolina, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Taiwan
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	cetuximab, CGX1321, encorafenib, Pembrolizumab, Keytruda
Tags	MSS/ MMRp
NCT ID	NCT03727763
Title	Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Phase	Phase 2
Date Added	2018-11-01
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	cetuximab, Vemurafenib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05291156
Title	CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
Phase	Phase 2
Date Added	2022-03-22
Location	Italy
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting

Drugs	Avelumab, cetuximab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03297606
Title	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase	Phase 2
Date Added	2017-09-29
Location	Canada
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temsirolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05426005
Title	Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2022-06-21
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Cadonilimab
Tags	MSI-H/ MMRd